FDA
-
-
-
-
-
-
-
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
-
-
-
-
-
-
-
Sangamo BioSciences (SGMO) Partner Pfizer Announced Hemophilia-A Clinical Hold Lifted, 'A Clear Positive for SGMO' - RBC
-
-
-
-
-
-
-
Sangamo Therapeutics (SGMO) Reports Positive Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data
-
-
-
-
-
-
-
Sangamo Therapeutics (SGMO) Misses Q1 EPS by 2c, Revenues Beat
-
-
-
-
-
-
-
Pre-Open Stock Movers 08/19: (MNTA) (HUD) (IMVT) Higher; (BMRN) (GLPG) (VIPS) Lower (more...)
-
-
-
-
-
-
-
Sangamo Therapeutics (SGMO) Reports Preilm. Results from 1st Three Patients in Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-Edited Cell Therapy in Beta Thalassemia
-
251,770 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All